Patents Assigned to IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 11911518
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: February 27, 2024
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 11241391
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: February 8, 2022
    Assignee: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
    Inventors: David Lickrish, Feng Zhang
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 11241392
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: February 8, 2022
    Assignee: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
    Inventors: David Lickrish, Feng Zhang
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 10905652
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: February 2, 2021
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 10881618
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: January 5, 2021
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 10617651
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: April 14, 2020
    Assignee: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
    Inventors: David Lickrish, Feng Zhang
  • Methods of treatment of attention deficit hyperactivity disorder
    Patent number: 10292937
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 7 hours or longer, followed by an ascending release rate. When administered at night the composition provides early morning improvement in symptoms of ADHD and sustained improvement over a period of at least 12 hours.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: May 21, 2019
    Assignee: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
    Inventors: David Lickrish, Feng Zhang
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 10182995
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 22, 2019
    Assignee: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
    Inventors: David Lickrish, Feng Zhang
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 10179108
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) and other CNS stimulant responsive conditions include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by an extended release.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: January 15, 2019
    Assignee: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
    Inventors: David Lickrish, Feng Zhang
  • Methods for treatment of attention deficit hyperactivity disorder
    Patent number: 9889095
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: February 13, 2018
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Methods of treatment of attention deficit hyperactivity disorder
    Patent number: 9603809
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 7 hours or longer, followed by an ascending release rate. When administered at night the composition provides early morning improvement in symptoms of ADHD and sustained improvement over a period of at least 12 hours.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: March 28, 2017
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Method of treatment of attention deficit hyperactivity disorder
    Patent number: 9603808
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: March 28, 2017
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 9511032
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) and other CNS stimulant responsive conditions include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by an extended release.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: December 6, 2016
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 9498447
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: November 22, 2016
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Compositions for Treatment of Attention Deficit Hyperactivity Disorder
    Publication number: 20160193156
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Application
    Filed: March 14, 2016
    Publication date: July 7, 2016
    Applicant: Ironshore Pharmaceuticals & Development, Inc
    Inventors: David Lickrish, Feng Zhang
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 9289394
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: March 22, 2016
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 9283214
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: March 15, 2016
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 9119809
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: September 1, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Method of Treatment of Attention Deficit Hyperactivity Disorder
    Publication number: 20150238443
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.
    Type: Application
    Filed: May 12, 2015
    Publication date: August 27, 2015
    Applicant: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Methods for treatment of attention deficit hyperactivity disorder
    Patent number: 9034902
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 19, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang